In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
Search results for: cardiovascular disease
Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More
In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.
OA Prevalence Primarily on the Rise
Background & Objectives Worldwide, osteoarthritis (OA) is a highly prevalent, chronic joint disease that causes pain, disability and loss of function. Global trends demonstrated an increase of more than 100% in years lived with disability due to OA from 1990 to 2019. However, no nonsurgical intervention exists to prevent, halt or even delay OA progression….
ACR-FDA Summit Focuses on Study Design, Safety Considerations
Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.
Gout Experts Share Insights Into a Variety of Challenging Gout Scenarios
Although the diagnosis and treatment of gout are sometimes straightforward, practitioners encounter challenges in patients with atypical presentations, as well as those with medically complex situations or refractory disease. Here, gout experts share insights into some of these scenarios. Flare in Hospitalized Patients When not contraindicated, the 2020 ACR Guideline for the Management of Gout…
Diagnostic Challenges of MIS-C
During the peak of the coronavirus pandemic in Washington, D.C., we were asked to evaluate a 14-year-old boy admitted to the pediatric hospitalist service. He had been healthy until two weeks before, when he noted a sore throat, and soon after he developed fevers and rashes without congestion, shortness of breath, conjunctivitis or swollen lymph…
Case Report: Blunt Smoker Denies Tobacco Use, Delaying Diagnosis
Cannabis arteritis mirrors thromboangiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight into how cannabis may…
Spring 2022’s Awards, Appointments & Announcements in Rheumatology
Martin Kriegel, MD, PhD, Receives 2021 Lupus Insight Award “I have always found the conundrum of autoimmunity interesting. It’s fascinating to find out why the immune system attacks the body, how it can distinguish self from non-self,” says Martin Kriegel, MD, PhD, head of the Department of Translational Rheumatology & Immunology, Institute of Musculoskeletal Medicine,…
Research Roundup: Abstract Data Presented at ACR Convergence 2021
The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…
An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report
According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 64
- Next Page »